Lv51
1372 积分 2021-03-03 加入
EZH2 promotes the progression of osteosarcoma through the activation of the AKT/GSK3β pathway
21天前
已完结
EZH2 inhibition for epithelioid sarcoma and follicular lymphoma
22天前
已完结
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
1个月前
已完结
Targeting p16INK4a-mediated cellular senescence as a therapeutic strategy for FLT3-ITD-driven acute myeloid leukemia
1个月前
已完结
Blood Cultures in Persistent Febrile Neutropenia: Finding the Sweet Spot
1个月前
已关闭
61 | A PIVOTAL STUDY OF SHR2554, AN ORAL INHIBITOR AGAINST ENHANCER OF ZESTE HOMOLOG 2 (EZH2), IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL)
1个月前
已完结
Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases
2个月前
已完结
Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
2个月前
已完结
EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy
2个月前
已完结
Unraveling the many faces of angioimmunoblastic T-cell lymphoma: clinical, pathological, and molecular heterogeneity
2个月前
已完结
皖公网安备34019202002308
